 |
 Video: What is a Stock Split?
|
|
|
| Aridis Pharmaceuticals is a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapy using human monoclonal antibodies (mAbs) to treat infections. Co.'s product candidates include: AR-301, which is a human immunoglobulin 1 (IgG1) mAb targeting the gram-positive bacteria S. aureus alphatoxin; AR-320, which is a human, IgG1 monoclonal antibody targeting S. aureus alpha toxin; AR-501 (Panaecin), which is a spectrum small molecule anti-infective Co. is developing in addition to its targeted mAb product candidates; and AR-701, which is a is a cocktail of human mAbs that are directed at multiple protein epitopes on the SARS-CoV-2 virus. According to our ARDS stock split history records, ARDS has had 0 splits. | |
|
ARDS (ARDS) has 0 splits in our ARDS stock split history database.
Looking at the ARDS stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ARDS shares, starting with a $10,000 purchase of ARDS, presented on a split-history-adjusted basis factoring in the complete ARDS stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
08/15/2018 |
|
| End date: |
07/27/2023 |
|
| Start price/share: |
$12.96 |
|
| End price/share: |
$0.22 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-98.30% |
|
| Average Annual Total Return: |
-56.10% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$169.81 |
|
| Years: |
4.95 |
|
|
|
|
|
